DEPRESCRIBING GUIDE FOR REGULAR LONG-TERM OPIOID ANALGESIC USE (>3 MONTHS) IN OLDER ADULTS
(including morphine, hydromorphone, fentanyl, oxycodone, buprenorphine, codeine)

STEP 1: WHY SHOULD I DEPRESCRIBE? (PATIENT ASSESSMENT)

Deprescribing triggers:

• Inappropriate indication, no current indication, presence or risk of adverse events, drug interaction, drug-disease interaction, high drug burden index (DBI), poor adherence, lack of adequate response, need for escalating dose without adequate response, aberrant behaviours developed, or patient preference.

1a) Is there a documented indication or symptom supporting continued use?

Inappropriate indication for continued use:

• Resolution of painful condition.
• Lack of adequate improvement in pain control (e.g. allodynia or hyperalgesia) and/or function.
• Medical (including mental health) conditions and other medicines that increase risk of opioid overdose.
• Treatment of painful conditions where opioid analgesics are not effective (e.g. low back pain, fibromyalgia).

Do not deprescribe as a sole provider and consider involvement of specialist pain management team or drug and alcohol services if:

• Complex severe pain is present.
• There are associated risks if weaned (e.g. substance use disorder, worsening of mental health conditions, unstable adverse social circumstances).
• Response to non-opioid or non-drug therapeutic interventions has been poor.
• Enrolled in a drugs of dependence program.

1b) Are there adverse effects?

Consider potential adverse events from opioid therapy:

• Falls, dizziness, orthostatic hypotension, itch, dry mouth, meiosis, urinary retention, nausea, vomiting, dyspepsia, constipation, respiratory depression, headaches, cognitive impairment (e.g. confusion), drowsiness, over-sedation, impaired concentration (e.g. increase risk of car accidents), mood changes or dependence.

1c) Is this medication likely to cause more harm than benefit?

Consider the risk of dose-related harm from opioid analgesics. This can be estimated using oral morphine equivalent daily dose (OMEDD), with a substantial increase in harm seen with OMEDD >20 mg.

See Evidence-based advice for additional information on risks of harm and benefits of continued use.

1d) Does the patient/carer agree with the recommendation to deprescribe?

Following provision of information, discussion and shared-decision making, the patient or carer has communicated that they would like to proceed with or decline the deprescribing recommendation.

PREFERRED LANGUAGE:
(Adapt for each patient and medicine as appropriate)

__________ is currently taking ____________________________
for ____________________________, and is currently experiencing/at risk of ____________________________.
The _______________ outweighs the _______________ for continued use of ____________________________.

Discussed with _______________ and _______________ deprescribing recommendation.

This guide provides deprescribing information that can be applied to written and/or verbal communication (in the form of “preferred language”) between clinicians, patients and/or carers. This guide is adapted for older adults (>65 years) in hospitals. It may not apply to programs targeting drugs of dependence (e.g. methadone programs) and palliative care. Adapt appropriately for individual patients.

CONSIDER TWO STEPS WHEN DEPRESCRIBING:

1. Should I deprescribe?
2. How do I deprescribe?
STEP 2: HOW SHOULD I DEPRESCRIBE?  
(RECOMMENDATION AND MANAGEMENT)

2a) How to wean

**Key Points**
- Establish a supportive and trusting relationship with the patient to engage in complex/sensitive discussions.
- In general, wean gradually by 5-25% of the daily dose every 1-4 weeks.
  - Initiate weaning faster if deprescribing due to adverse effects.
  - Initiate weaning slower if starting from a high dose and/or long duration of use.
- Consider judicious and appropriate use of simple analgesics.
- Involvement of and close liaison with patient’s general practitioner (GP) with follow-up appointments (frequency determined by rate of weaning).
- Substitution with other opioid medicines for initial attempts to wean is not recommended as the same adverse effects and outcomes occur. However, in some circumstances, changing to another medication/formulation that is easier to wean may be considered.

### Initiation

Reduce dose rapidly by 10-25% of the daily dose each week, or slowly by 5-25% each month.³

**Option 1:** Rationalise the regimen to a single modified release opioid. When stabilised, the dose should be reduced.

**Option 2:** Keep the modified-release dose stable first and wean down the immediate release as needed (prn) doses. When stabilised, reduce the modified-release dose by around 5-10% per dose per week. May need limited prn immediate release during weaning. However, increasing the prn doses would negate the effect of the modified-release wean.

### Adjustments depend on response

Adjust according to pain response and tolerability of adverse drug or withdrawal effects (see Monitoring recommendations).
- If no withdrawal symptoms continue to wean and stop, otherwise pause longer between changes.
- Use slower weaning when reducing to the final lowest doses. End treatment 2-4 weeks after administering the lowest dose.
- If recurrent pain symptoms occur when all dosing has stopped, then restarting at the lowest tolerated dose may be reasonable.
- Consider alternate day dosing to aid weaning if dosage forms are limited.
- Monitor laxative requirements throughout weaning.

### Adjustments in the case of recurrent symptoms

In the case of recurrent/withdrawal symptoms, revert to the previous lowest tolerated dose. Recommence weaning after 6-12 weeks at lower weaning rate (e.g. 5-10% of daily dose each month) then stop.

(Based on recommendations in References²⁻¹⁷)

---

**PREFERRED LANGUAGE:**
(Adapt for each patient and medicine as appropriate)

Recommend pain self-management strategies to reduce reliance on regular use of opioid medicines.

Recommend gradually reducing to [drug: e.g. oxycodone/naloxone SR (Targin MR) 10/5mg mane, 5/2.5mg nocte](timeframe: e.g. 1 week) for _______________ and reassess.

Recommend further tapering by [proportion: e.g. 25%](timeframe: e.g. week) every with further adjustments guided by response. Follow up with GP _______________ after discharge.

Note: Examples of preferred language are provided for ‘Option 1’ and can be adapted to cover other regimens.
2b) Alternative management

Pain self-management skills training

A multidisciplinary approach to improve pain self-management skills including psychological (e.g. cognitive behavioural therapy including goal setting, pacing, flare-up plan and monitoring unhelpful thoughts and emotions to pain), physical (e.g. graded exercise program to improve range of motion, muscle strength and posture) and other approaches (e.g. counselling, meditation, relaxation, massage and dietary changes).\(^{18,19}\)

For advice on pain self-management strategies, refer to [AMH Aged Care Companion-Pain management] and [Pain Management Network – Management of chronic pain] and [NSW TAG-Preventing and managing problems with opioid prescribing for chronic non-cancer pain].

Switching within drug class or consider alternative therapy

Consider indication, duration of therapy, type of formulation and patient risk factors when switching or weaning.

If weaning a transdermal patch, wean to the lowest tolerable patch strength, then consider switching to an alternative oral modified-release opioid and continue to wean with frequent monitoring.\(^{13}\)

Refer to opioid conversion tables at [AMH-Opioid comparative information].

2c) Monitoring

<table>
<thead>
<tr>
<th>Monitor short term (within 1-3 days)</th>
<th>Monitor long term (&gt;1 week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Withdrawal symptoms can occur within 1-3 days of dose reductions.</td>
<td>Recurrence of previous or new pain symptoms may occur within 1-2 weeks of dose reductions.</td>
</tr>
</tbody>
</table>

- Common withdrawal symptoms (e.g. nausea, vomiting, sweating, anxiety, craving, dilated pupils, goose pimples, diarrhoea, cramps, muscle aches, restlessness, insomnia, tearing, tachycardia, increased BP) are usually mild, highly variable and can last up to 6-8 weeks.
- If severe symptoms (e.g. dehydration due to nausea, vomiting, profuse and persistent sweating, tachycardia, severe anxiety, or severe insomnia), restart at the previous lowest effective dose.
- To refer to opioid withdrawal treatment, refer to [AMH-Opioid dependence].
- Continue to reduce medications even if pain returns. For a flare-up plan, refer to [Pain Management Network – Flare-Up Plan] and [NSW TAG-Preventing and managing problems with opioid prescribing for chronic non-cancer pain].

PREFERRED LANGUAGE:

Within 1-3 days of dose reduction, monitor for withdrawal of symptoms which can be mild (e.g. nausea, vomiting, sweating, anxiety, craving, insomnia) or severe (e.g. dehydration due to nausea, vomiting, profuse and persistent sweating, tachycardia, severe anxiety, or severe insomnia).

Monitor for recurrence or flare-up of pain within 1-2 weeks of dose reduction.

With severe symptoms, consider the value of restarting at lowest tolerated dose with a retrial of deprescribing at 6 weeks. Develop a pain flare up plan or seek further assistance prior to trying again.
Effectiveness and safety

The relative potency of opioids can be estimated by converting to an approximate oral morphine equivalent daily dose (OMEDD). National and state guidelines state that OMEDD of >60 mg in general, or >30 mg in older adults, those with impaired respiratory, renal or hepatic function and those taking other medicines with sedating effects are considered high risk and specialist advice is recommended.

The risk of serious harm (e.g. accidental overdose, death, hospitalisation, unconsciousness, respiratory failure) increases substantially for patients taking opioid analgesics >20 mg OMEDD for chronic non-cancer pain. In a cohort study (mean age ± SD 54 ±17 years), compared with patients taking 1-20mg OMEDD, the risk of serious harm was almost 1.5 times higher for those taking 20-50 mg OMEDD (hazard ratio [HR]=1.44, [95% CI; 0.57-3.62]); almost 4 times higher in those taking 50-100 mg OMEDD (HR=3.73, [95% CI; 1.47-9.50]); and almost 9 times higher in those taking >100 mg OMEDD (HR=8.87, [95% CI; 3.99-19.72]).

In people aged over 65 years, opioids are associated with an 88% increased risk of overall fractures (RR=1.88; 95% CI 1.51-2.34) and 2-fold increased risk of hip fractures (RR=2.00; 95% CI 1.84–2.19).

In a meta-analysis of patients with osteoarthritis of the knee or hip, in whom oral or transdermal opioids were deprescribed, only 24 out of 1000 people (2.4%) experienced withdrawal symptoms. For 1 person to experience withdrawal symptoms, 65 patients needed to be withdrawn from an opioid (i.e. number needed to harm [NNH 65], 95% CI 42 - 110).

Recommended duration of use

Limit opioid treatment to short-term use (<3 months). While opioids are effective in treating acute pain, their role in chronic non-cancer pain is limited.

Opioids are associated with significant harm (e.g. falls, fractures), and long-term use is not recommended, especially in older adults.

SUMMARISED PHRASING DURING HOSPITAL ADMISSION AND/OR AT DISCHARGE

When communicating deprescribing decisions to GPs at discharge, written and verbal communication should include information in the sequence of:

"Medicine, Intention, Rationale, Clear Plan (dose change, duration, follow up), Patient agreement"

<table>
<thead>
<tr>
<th>Medication(s) prior to weaning</th>
<th>stopped/ reduced</th>
<th>aim of stopping</th>
<th>specific rationale</th>
<th>of/ on current indication</th>
<th>due to</th>
<th>outweighing effects</th>
<th>patient/ carer agreed</th>
</tr>
</thead>
<tbody>
<tr>
<td>(e.g. Oxycodone/naloxone SR [Targin MR])</td>
<td>with aim of stopping</td>
<td>(e.g. delirium)</td>
<td>(e.g. on chronic pain)</td>
<td>(e.g. chronic pain)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If weaning:

<table>
<thead>
<tr>
<th>dose prior to weaning</th>
<th>reduced by</th>
<th>proportion</th>
<th>timeframe</th>
<th>follow-up action</th>
</tr>
</thead>
<tbody>
<tr>
<td>(e.g. Oxycodone/naloxone SR [Targin MR]) 10/5mg BD</td>
<td></td>
<td>(e.g. x%)</td>
<td>(e.g. 1 week)</td>
<td>(e.g. GP follow up, consider physiotherapy referral)</td>
</tr>
</tbody>
</table>

Example:


15. Medstopper. Available at http://medstopper.com


Copyright and Disclaimer

© 2019 Northern Sydney Local Health District, NSW Therapeutic Advisory Group Inc., Sydney Local Health District, the University of Sydney and Macquarie University.

The Work on this webpage and the copyright Works downloaded via this webpage are copyright remain the joint property of Northern Sydney Local Health District, NSW Therapeutic Advisory Group Inc., Sydney Local Health District, the University of Sydney and Macquarie University. By downloading this PDF, you are accepting our Terms and Conditions. You may download, display, print and reproduce the Works in unaltered form only (retaining this notice or the notice imprinted into the original download), with all other rights reserved. Any enquiries in regards to copyright, sharing the copyright Works, or requests for further authorisations should be directed in writing to Prof Sarah Hilmer at sarah.hilmer@sydney.edu.au.